Stay updated on IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The record describes a completed Phase 2 metastatic melanoma study of tilsotolimod with ipilimumab, with details on eligibility, study sites, treatment, and outcome measures. It also includes study documents and record dates.
    Difference
    57%
    Check dated 2026-11-07T12:11:41.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The displayed site revision changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:50:17.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A notice appears at the top of the page announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-24T13:23:01.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The site's footer revision identifier changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T14:30:32.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The site footer now identifies the release as v3.7.1 instead of v3.7.0. The page continues to show a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-10T14:20:47.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Access to the study record is blocked by a 403 Forbidden error, preventing viewing the study details. This reflects a site access issue rather than a substantive update to the content.
    Difference
    19%
    Check dated 2026-09-19T18:36:57.000Z thumbnail image

Stay in the know with updates to IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IMO-2125 Combo With Ipilimumab in Melanoma Clinical Trial page.